News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Heidelberg Pharma reduces costs and focuses on lead ADC candidate HDP-101 due to delayed milestone payment. Extensive cost-saving measures implemented -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Heidelberg Pharma significantly reduces operating costs and focuses on lead ADC candidate HDP-101 due to delayed milestone payment. Extensive cost-saving measures implemented -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Heidelberg Pharma announces new clinical data for lead ATAC candidate HDP-101 to be presented at the International Myeloma Society Annual Meeting 2025 -